If NAION is confirmed, treatment with semaglutide should be stopped
About the Author Lisa Catanese, ELS, Health Writer About the Reviewer Howard E
(13) Preclinical studies have demonstrated that GLP-1 receptor agonists like exenatide can enhance bone mass in diabetic and insulin-resistant rat models by upregulating OPG expression and improving the OPG/RANKL ratio
In microglial BV2 cells semaglutide dose-dependently inhibited apoptosis induced by -amyloid (1-42) and promoted the transformation of microglia from M1 to M2, thereby exerting anti-inflammatory and neuroprotective effects [50]
This off-label use, the authors argue, is exposing deeper tensions between medical innovation, weight stigma, and the social value attached to thinness, as medication becomes a means of attaining social and aesthetic goals rather than improving health
What are the different GLP-1 options